Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2) - CA088-1007
Zaktualizowano:
23 styczeń, 2025
|
ClinicalTrials.gov
Etap
Płeć
Zakres wieku
Lokalizacje
Recruiting
Inclusion Criteria - Participants must have relapsed or refractory multiple myeloma (RRMM). - Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody, and be refractory to lenalidomide (LEN) (progression on or within 60 days of completing LEN therapy). - Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria. - Participants must have measurable disease during screening. - Participants must have adequate organ function. - Participants must have an Eastern Cooperative Oncology group performance status 0 or 1. Exclusion Criteria - Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM). - Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease. - Participants must not need urgent treatment due to rapidly progressing MM. - Other protocol-defined Inclusion/Exclusion criteria apply.